No peer-reviewed human trials specifically measuring CJC-1295 administered as a nasal spray have been identified in the scientific literature reviewed for this article. This means that even though CJC-1295 nasal sprays are sold commercially, their effectiveness compared to injection has not been established through independent, published studies. This is a distinction worth plainly understanding before we look at what is and is not known.
What is CJC-1295 nasal spray?
CJC-1295 nasal spray is a liquid peptide formulation designed for absorption through the nasal mucosa – the moist tissue lining the inside of the nose – rather than subcutaneous injection. Products of this type are currently marketed by various commercial sources as an alternative to subcutaneous injection. The basic concept itself is not fundamentally implausible. The idea is that the peptide could be absorbed by the nasal lining and thus enter the bloodstream. The nasal mucosa is indeed richly supplied with blood and is a recognised route of administration for many other peptide-based drugs in general medicine.
However, it is important to make a clear distinction here. „The concept is plausible” and „this specific product has been proven to work” are two very different claims. The peer-reviewed literature reviewed for this paper does not contain any dedicated pharmacokinetic study measuring how much CJC-1295 specifically is actually absorbed into the bloodstream when administered as a nasal spray. Nor does it measure what hormonal effect, if any, results from this route of administration.
How effective is CJC-1295 nasal spray?
In the absence of a dedicated study on the intranasal bioavailability of CJC-1295, this question cannot be answered directly on the basis of the available evidence. However, there are relevant comparative data from a closely related compound, which provide useful context. A controlled pharmacokinetic study of ipamorelin – a ghrelin receptor peptide often combined with CJC-1295 – directly tested intranasal administration in animal studies. It showed that bioavailability via this route is approximately 20%. This means that roughly one-fifth of the dose reached the systemic circulation compared with injection. This was significantly lower than some structurally related peptides tested in the same study, several of which exhibited bioavailability closer to 50% [1].
This tells us two useful things. Firstly, that the growth hormone-releasing peptides, as a chemical family, are capable of at least some nasal absorption. The basic biology is therefore not implausible. Secondly, that nasal absorption efficiency varies significantly between individual peptides, even within the same structural family. This means that nasal bioavailability numbers for Ipamorelin cannot simply be assumed to be equally applicable to CJC-1295 – a chemically distinct and significantly larger molecule, especially in its DAC-bound form.
Without dedicated research, no evidence-based percentage of bioavailability or efficacy comparison with injection can be given specifically for nasal spray CJC-1295. Any such figures appearing in commercial marketing of these products should be understood as claims by the manufacturer, rather than independently verified research.
Dosage and how to use CJC-1295 nasal spray
No published pharmacokinetic or clinical studies have established that CJC-1295 nasal spray reliably delivers an effective dose of the peptide into the systemic circulation. For this reason, this article does not provide dosing, usage instructions, or frequency recommendations for this product. Doing so would require fabricating numbers that do not exist in the evidence base of peer-reviewed literature. This gap is more significant than it might initially seem. Even if the nasal spray contains an accurately labelled amount of CJC-1295 in the bottle, the actual amount absorbed into the bloodstream after administration of the nasal spray depends on numerous physiological factors. These include the condition of the nasal mucosa, the technique employed, and individual variability between people – none of which have been studied for this particular compound. This means that the labelled dose and the effective dose could vary significantly in ways that are simply not known.
This article also does not recommend or indicate any specific supplier or retail source for these products. This aligns with a broader principle worth remembering: unregulated peptide products, including specialised delivery formats such as nasal sprays, carry documented concerns regarding product quality, purity, and accurate labelling. These concerns have been raised in reviews of this category of compounds more broadly [2].
Limitations of current evidence
The central constraint running through this entire thread is simple. CJC-1295 nasal spray is a commercially available product but unresearched – at least based on the peer-reviewed literature reviewed for this article.
The data that actually exists regarding intranasal ipamorelin bioavailability provides informative background for the general concept of nasal peptide delivery. However, it cannot be used to draw firm conclusions specifically about CJC-1295, as it is a different, structurally distinct molecule that has not been tested via this route in any study identified herein.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice, dosing guidance, or product endorsement. CJC-1295, in any form of administration, is a research compound and is not approved by the FDA or European Medicines Agency for any medical use. No published pharmacokinetic or clinical studies have measured the absorption, efficacy, or safety of CJC-1295 administered specifically as a nasal spray. Commercial claims regarding the bioavailability or efficacy of the nasal spray have not been independently verified through peer-reviewed research.
References
[1] Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976
[2] Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: A critical review. Journal of Sports Medicine and Physical Fitness, 66(7), 880–885. https://doi.org/10.23736/S0022-4707.26.17773-1